(12) **Translation of European patent specification**

(11) **NO/EP 3556351 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 9/08 (2006.01)
A61K 9/14 (2006.01)
A61K 31/375 (2006.01)
A61K 31/519 (2006.01)
A61K 33/26 (2006.01)
A61K 47/26 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.10.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.08.09
(86)	European Application Nr.	19386016.0
(86)	European Filing Date	2019.03.22
(87)	The European Application's Publication Date	2019.10.23
(30)	Priority	2018.04.16, GR, 20180100160
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Tseti, Ioulia, 13 Pavlou Mela Street, 145 61 Kifissia Attica, Hellas
(72)	Inventor	Tseti, Ioulia, 13 Pavlou Mela Street, 145 61 Kifissia Attica, Hellas
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **A PHARMACEUTICAL COMPOSITION FOR ENHANCING IRON LEVELS IN BLOOD, COMPRISING IRON (III) POLYMALTOSE AND ANOTHER ACTIVE SUBSTANCE, SUITABLE FOR IRON ABSORPTION, SELECTED FROM CALCIUM FOLINATE PENTAHYDRATE, VITAMIN C OR A COMBINATION OF BOTH**

(56) References Cited:

EP-A1- 0 427 078
EP-A1- 1 790 356
US-A- 4 931 441
WO-A1-2007/042153
EP-A1- 2 674 371

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Farmasøytisk sammensetning for bruk som en enkeltdose oral oppløsning omfattende jern(III) polymaltosekompleks, kalsiumfolinat og vitamin C, hvori jern(III) polymaltosekomplekset er lagret som en løsning i en sylindrisk flaske og kalsiumfolinat og vitamin C lagres atskilt fra nevnte løsning, i fast form, i et lagringsrom i lokket til flasken.

2. Farmasøytisk sammensetning ifølge krav 1, hvori jern(III)-polymaltosekomplekset er standardisert i 32 ± 4 % vekt/vekt i treverdig jern.

3. Farmasøytisk sammensetning ifølge krav 1 og 2, hvori mengden av treverdig jern er 100 mg per doseringsenhet oral løsning.